ClinicalTrials.gg
Not yet recruitingNCT07352904STRAT-JVNUpdated Aug 28, 2026

Exploration Strategies in Night Vision Sensors

An observational study in Visual Acuity, sponsored by Direction Centrale du Service de Santé des Armées. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Direction Centrale du Service de Santé des Armées · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of this clinical trial is to identify a variation in visual strategy characterized by both head movements and eye movements of healthy volunteers during a target detection task when images simulating night vision goggles (NVG) are presented, compared to a situation in which the images simulate a natural environment.

To highlight changes in environmental scanning with simulated images from NVG, objective measurements will be collected:

  • eye movements characterized by saccades (speed, latency, and number) for each stimulus
  • head movements (horizontal angle of the participant's head) for each stimulus and throughout the exposure

Participants sit facing a screen (9.90 m x 2.10 m) onto which a virtual scene is projected. The objective is to correctly identify, as quickly as possible, a target stimulus (represented by a tank) that may appear in the scene. They must use the directional arrows on a game controller to indicate whether the tank is moving to the left or to the right.

There are four visits involving four viewing conditions in which the task remains the same:

  • With restricted field of view and a normal scene.
  • Without restricted field of view and a scene simulating the vision obtained by NVGs.
  • With restricted field of view and a scene simulating the vision obtained by NVGs.
  • Without restricted field of view and a normal scene. Regarding the content of the scene, half of the tests in each visit involve a so-called poor scene when fog is simulated, or an enriched scene when there is no fog. Each visit lasts approximately one hour and thirty minutes.
02

Conditions studied

  • Visual Acuity

Browse trials for

Keywords

  • visual strategy
  • Night Vision Goggles
  • eyetracking
  • visual fatigue
03

In context

Asthenopia

67 studies on the registry are indexed under Asthenopia; 10 are open to participants now.

Browse Asthenopia studies →

Lead sponsor

Direction Centrale du Service de Santé des Armées is the lead sponsor of 95 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

French volunteers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Affiliated with social security;
  • Normal vision or vision corrected with lenses (far vision ≤ 0.03 log unit (≥ 9/10) OD/OG/binocular);
  • No current or past ocular or binocular pathology: strabismus or amblyopia;
  • Signed non-objection form.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women;
  • Incapacitated adults;
  • Individuals who do not understand French (written or spoken).
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Eye movements characterized by saccades (speed, latency, and number) for each stimulus

    Measurements from eyetracker

    Time frame: Day 1 (Visit 1) and during follow-up visits at Day 2 (Visit 2), Day 3 (Visit 3), and Day 4 (Visit 4)

  2. Head movements (horizontal angle of the participant's head) for each stimulus and throughout the exposure

    Measurements extract from motion capture

    Time frame: Day 1 (Visit 1) and during follow-up visits at Day 2 (Visit 2), Day 3 (Visit 3), and Day 4 (Visit 4)

Secondary outcomes

  1. The average stimulus detection times.

    Measurements from an eyetracker

    Time frame: Day 1 (Visit 1) and during follow-up visits at Day 2 (Visit 2), Day 3 (Visit 3), and Day 4 (Visit 4)

  2. Number of correct responses to the perceptual task

    Extract with software

    Time frame: Day 1 (Visit 1) and during follow-up visits at Day 2 (Visit 2), Day 3 (Visit 3), and Day 4 (Visit 4)

  3. Visual fatigue will be measured using a questionnaire

    To highlight subjective visual fatigue generated by changes in visual search strategies using simulated images from night vision sensors.

    Time frame: Day 1 (Visit 1) and during follow-up visits at Day 2 (Visit 2), Day 3 (Visit 3), and Day 4 (Visit 4)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Jan 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 25, 2026
CompletionEst.
Dec 25, 2026
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07352904
Lead sponsor
Direction Centrale du Service de Santé des Armées
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 25, 2026 (estimated)
Completion
Dec 25, 2026 (estimated)
Last update
Aug 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion